Cancer Gene Therapy Market Analysis

Cancer Gene Therapy Market Analysis

To get key market trends

  Download Free Sample

Based on the type, the market is classified into ex-vivo and in-vivo. The in-vivo segment dominated the market with revenue of USD 1.2 billion in 2023.

• The development of targeted therapies and personalized medicine approaches is driving the demand for in-vivo cancer gene therapy.

   

• Also, in-vivo type of gene delivery systems are being widely used to enhance the expression of immunomodulatory genes or chimeric antigen receptors (CARs) in immune cells, boosting anti-tumor immune responses and improve the efficacy of immunotherapy in cancer patients. Thus, aforementioned factors are expected to accelerate the market growth.

Based on the therapy, the global cancer gene therapy market is classified into oncolytic virotherapy, gene-induced immunotherapy, and gene transfer. The gene-induced immunotherapy dominated the market with revenue of USD 873.7 million in 2023.

• Gene-induced immunotherapy holds the potential to induce long-term remission or even cure in some cancer patients, which is a significant driver for its adoption in the market.

   

• Additionally, advances in gene editing technologies such as CRISPR-Cas9 have revolutionized the field of gene therapy, enabling precise editing of genes associated with cancer immunotherapy. These technological advancements are driving the development of novel gene-induced immunotherapy approaches, thereby augmenting the market growth.

   

Based on product, the cancer gene therapy market is classified into viral vectors, non-viral vectors, and other products. Viral vectors segment held the highest market share of 46.6% in 2023.

• Cancer gene therapy is witnessing the emergence of new viral vector platforms beyond traditional vectors such as retroviruses and adenoviruses. Lentiviral vectors, adeno-associated viruses (AAVs), and other engineered viral vectors are being explored for their potential advantages in delivering therapeutic genes to cancer cells.

   

• Also, growing interest in combining viral vector-based gene therapies with other treatment modalities, such as chemotherapy, radiation therapy, immunotherapy, and small molecule inhibitors to enhance therapeutic efficacy, overcome treatment resistance, and improve patient outcomes in various cancer types will spur the growth of the market in the coming years.

   

Based on end-use, the cancer gene therapy market is classified into research institutes, biopharmaceutical companies, and other end-users. The biopharmaceutical companies segment is expected to exhibit 21% CAGR between 2024 - 2032.

• The market is propelled by the growing utilization of fundamental gene therapy approaches by major biopharmaceutical companies to develop cancer treatment regimens. Moreover, numerous innovative therapeutic medications are undergoing various trial phases, with companies aiming to introduce for wide range of cancer treatment. Therefore, companies with significant product pipeline along with growing incidence of cancer are anticipated to foster the market expansion.

In 2023, North America secured a substantial market share of 43.7% in the global cancer gene therapy market and is expected to dominate throughout the forecast period.

• The factors such as significant investment in research and development, presence of key players, and collaborations between biopharmaceutical companies, research institutions, and healthcare providers are driving the growth of North America market.

   

• Also, government agencies such as the National Institutes of Health (NIH) in the U.S. allocate substantial funding to support cancer research, including gene therapy. This funding supports basic research, translational studies, and clinical trials focused on developing and refining gene therapy approaches for various types of cancer.